Hidradenitis suppurativa and diabetes mellitus: A systematic review and meta-analysis - 13/01/18
Abstract |
Background |
The relationship between hidradenitis suppurativa and diabetes mellitus is not well understood.
Objective |
To compare the prevalence of diabetes mellitus between patients with and without hidradenitis suppurativa.
Methods |
We conducted a systematic review and meta-analysis, which included primary observational studies that reported the prevalence of diabetes mellitus among patients with hidradenitis suppurativa in the PubMed, Embase, Cochrane Library, LILACS, and Scielo databases from 1947 to June 13, 2017. A random effects model for pooled odds ratio was used for data analysis. Publication bias was assessed by funnel plot and the Egger test.
Results |
The systematic review included 107,050 patients from 14 studies; the meta-analysis included 104,373 patients from 7 studies. On the basis of meta-analysis, the prevalence of diabetes mellitus was 10.6% in patients with hidradenitis suppurativa and 3.8% in patients without hidradenitis suppurativa. Compared with the general population, patients with hidradenitis suppurativa were nearly 3 times more likely to have diabetes mellitus (pooled odds ratio, 2.78; 95% confidence interval, 1.79-4.31).
Limitations |
We were restricted by the quantity and quality of available data.
Conclusion |
Hidradenitis suppurativa is significantly associated with an increased prevalence of diabetes mellitus.
Le texte complet de cet article est disponible en PDF.Key words : diabetes mellitus, hidradenitis suppurativa, hyperglycemia, meta-analysis, prevalence, systematic review
Abbreviations used : CI, DM, HS, MetS, OR
Plan
| Funding sources: None. |
|
| Disclosure: Dr Armstrong reports having served as an investigator and/or advisor to AbbVie, Eli Lilly, Janssen, Modernizing Medicine, Novartis, Pfizer, Regeneron, Sanofi, Science 37, and Valeant. Drs Bui, Silva-Hirschberg, and Torres have no conflicts of interest to declare. |
Vol 78 - N° 2
P. 395-402 - février 2018 Retour au numéro
Article précédent
- Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation
- Scott M. Whitlock, Clinton W. Enos, April W. Armstrong, Alice Gottlieb, Richard G. Langley, Mark Lebwohl, Joseph F. Merola, Caitriona Ryan, Michael P. Siegel, Jeffrey M. Weinberg, Jashin J. Wu, Abby S. Van Voorhees
- Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
- Lucy Y. Liu, Brittany G. Craiglow, Brett A. King
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?